The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

While the condition can impact quality of life and mental health, seeking treatment and support can make a powerful ...

ENS-002 leverages a carefully selected trio of microbes to subdue virulent, inflammation-causing S. aureus, a core microbial driver of atopic dermatitis, offering a potential novel avenue for ...

CRANBURY, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MJH Life Sciences ®, a premier provider of health care events, media, and education, today announced the acquisition of the Revolutionizing Atopic ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...